What is this study trying to find out about metastatic lung cancer?

This study aims to understand the health status, quality of life, and socioeconomic impacts for patients who have lived at least three years after a metastatic lung cancer diagnosis without cytotoxic chemotherapy. Researchers want to identify patients’ needs to improve care and support. The research is led by GFPC Investigation.

Who may be eligible for this metastatic lung cancer clinical trial?

Adults aged 18 or older diagnosed with stage III or IV NSCLC or SCLC who have survived at least three years and are not currently receiving cytotoxic chemotherapy may be eligible. Patients must be covered by French health insurance and able to communicate in French. Please review eligibility criteria for more details.

Is there any cost to participate in this metastatic lung cancer clinical trial?

Study-related care, including questionnaires and all study visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Age: 18Years +

All Genders

ID07243132

Long-Term Responders in Metastatic Lung Cancer Better Understanding for Better Management LUNGEVITY STUDY

Led by GFPC Investigation · Updated on 2026-04-27

1000

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying patients who have lived for three years or more after being diagnosed with metastatic lung cancer and who are no longer receiving cytotoxic chemotherapy. The study aims to understand these patients clinical characteristics, health status, socioeconomic impacts, quality of life, and their ability to return to work. This observational research focuses on both non-small cell lung cancer NSCLC and small cell lung cancer SCLC. Participants will be observed over time without receiving experimental treatments. They will complete several questionnaires related to quality of life, anxiety, and depression at the start of the study, then at 6 and 12 months, and annually for up to five years. Their health and treatment history, including any ongoing therapies like immunotherapy or targeted therapy, will be recorded throughout the study. During the study, participants will continue their usual medical care and attend regular consultations as needed. Researchers will collect data through questionnaires and health evaluations to measure clinical characteristics, health status, socioeconomic factors, and psychological well-being. The main outcomes include baseline clinical data and repeated assessments over five years to better understand long-term survivorship after metastatic lung cancer diagnosis.

CONDITIONS

Brief Title

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Patient over 18 years old
Alive for more than three years after diagnosis with stage IV or stage III NSCLC or SCLC
Not receiving cytotoxic chemotherapy at the time of inclusion (immunotherapy, targeted therapy, or surveillance allowed)
Covered by the French National Health Insurance program or third-party health insurance

You will not qualify if you...

Difficulty understanding French
Currently receiving cytotoxic chemotherapy
Under legal guardianship, curatorship, or tutorship
Insufficient cognitive ability to answer questions
Unable to collect data due to loss to follow-up or refusal
Refusal to allow collection of personal data

Research Team

Alice MOGENET

Soizic FERLANDIN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here